As genomics stocks bottom out, here’s who’s still on top
$7.1M William Rich, Ciphergen, CEO
$63.1M Mark Chandler, Luminex, CEO
$213.3M Lyle Turner, Invitrogen, CEO
$2.7M Mark Boguski, Rosetta Inpharmatics, Sr. VP of R&D
$6.9M William Matthews, Deltagen, CEO
$4.9M Mark Gessler, Gene Logic, CEO
$1.8M Stuart Collinson, Aurora Biosciences, CEO
$8.7M Howard Birndorf, Nanogen, CEO
$66.8M Mark Chee, Illumina, VP of Genomics
$76.0M Tony White, Applera, CEO
$5.3M Arthur sands, Lexicon Genetics, CEO
$6.3M Gregg Helt, Affymetrix, Principal Scientist
$1.3M Dale Pfost, Orchid BioSciences, President and CEO
$8.4M Cyrus Harmon, Affymetrix, VP of Computational Genomics
$1.7M John King, Rosetta Inpharmatics, COO
$9.7M Timothy Rink, Aurora Biosciences, Fmr. Chrm. and CEO
$40.5M Michael Hunkapiller, Applied Biosystems, President
$2.6M Tony Shuh, Sequenom, President and CEO
$4.1M Daniel Kisner, Caliper Technologies, CEO
$8.5M Stephen Fodor, Affymetrix, CEO
$1.1M Kieran Gallahue, Nanogen, CFO
$17.1M Roy Whitfield, Incyte Genomics, CEO
$42.2M Craig Venter, Celera Genomics, CSO
$15.3M Harden McConnell, Molecular Devices, Founder
$3.2M Calvin Chow, Caliper Technologies, COO
$3.9M Hannes Smarason, DeCode Genetics, Sr. Bus. & Finance Officer
$4.8M Joseph Keegan, Molecular Devices, CEO
$14.6M Emery Olcott, Packard Bioscience, CEO
$4.9M Joseph Limber, Aclara BioSciences, CEO
$18.4M Dennis Winger, Applied Biosystems, CFO
$2.9M Herbert Hooper, Aclara BioSciences, CSO
$38.8M Jeffrey Williams, Genomic Solutions, CEO
$21.9M Kari Stefansson, DeCode Genetics, CEO
$7.2M Jay Flatley, Illumina, CEO
$8.8M Randy Scott, Incyte Genomics, Chairman
$10.0M Richard McKernan, Packard BioScience, Sr. VP
$3.4M Jeffrey Gulcher, DeCode Genetics, VP, R&D
$5.9M Stephan Friend, Rosetta Inpharmatics, CEO
Values reflect individuals fully diluted company shares and options. All data based on most recent SEC filings available and March 29 share prices.